Table of Contents
Servier India Offers Free and Low-Cost Cancer Gene Tests
What was announced
- Who: Servier India (the Indian branch of the French pharma company Servier Group)
- When: The announcement was made on 11 November 2025.
- What: Launch of a programme offering free or subsidised testing for certain cancer-related biomarkers.
- Scope: The testing focuses on the genes IDH1 and IDH2, which have changes (mutations) in some cancer patients.
- Diseases covered: The cancers included are Acute Myeloid Leukaemia (AML) and Cholangiocarcinoma (CCA), a bile-duct cancer.
- Cost model: For patients in government hospitals the test will be free, and for private-sector patients it will be offered at subsidised rates.
- Partners: The programme is being run in collaboration with genomics labs MedGenome and Strand Life Sciences.
Why this matters
- Better diagnosis: Finding IDH1/IDH2 mutations helps doctors choose more appropriate treatments for AML and CCA.
- Bridging access gap: Until now, many patients in smaller cities or towns did not have easy access to advanced genetic testing.
- Reducing cost burden: Without this programme such tests can cost thousands to lakhs of rupees. This subsidy helps reduce that financial load.
- Potential for better outcomes: If diagnosis is done earlier and more exactly, the chances of effective treatment improve.
Programme details
- Test panel: A special set of tests (panel) designed to check for IDH1 and IDH2 gene-changes in these cancers.
- Sector availability: Tests are free in government hospitals; in private hospitals they are offered at much lower cost.
- Patient-support link: The initiative is part of the “Servier Care” support programme which helps with diagnostics, financial aid and access.
- Ordering mechanism: Doctors in both private and public sectors will be able to prescribe these tests and get samples sent in for analysis.
Practical implications for patients and clinicians
- For patients: If you or someone you know is being treated for AML or CCA, ask your doctor whether IDH1/IDH2 testing is available under this programme.
- For clinicians/hospitals: Reach out to MedGenome or Strand Life Sciences to find out how to enrol patients, arrange the test, send samples and get results.
- For underserved regions: This subsidy makes it possible for smaller hospitals and patients in non-metro areas to access advanced diagnostics which they may not have had earlier.
Important Questions
- Which cancers are included in the Servier India biomarker testing programme?
- Which specific genes are tested under the Servier India initiative?
- Which laboratories are partnering with Servier India for the biomarker testing?
- On what date was the Servier India biomarker testing programme launched?
- How will the Servier India programme benefit patients in government hospitals and smaller cities?
Conclusion
Servier India’s biomarker testing programme is an important step toward affordable cancer care. By providing free and subsidised tests for AML and bile duct cancer, it helps more patients access modern genetic testing, leading to quicker diagnosis and better treatment options across India.
3
